GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (CHIX:GISd) » Definitions » Total Long-Term Liabilities

Gilead Sciences (CHIX:GISD) Total Long-Term Liabilities : €21,994 Mil (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Gilead Sciences Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Gilead Sciences's Total Long-Term Liabilities for the quarter that ended in Sep. 2024 was €21,994 Mil.

Gilead Sciences Total Long-Term Liabilities Historical Data

The historical data trend for Gilead Sciences's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Total Long-Term Liabilities Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26,296.20 31,884.56 31,221.03 29,003.46 25,764.03

Gilead Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26,411.22 25,764.03 23,755.32 22,855.26 21,994.31

Gilead Sciences Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Gilead Sciences Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (CHIX:GISd) » Definitions » Total Long-Term Liabilities
Comparable Companies
BMY PFE AMGN BIIB OGN AMRN SCLX MIRA MRK ABBV LLY OCSE:NOVO B JNJ XSWX:ROG XSWX:NOVN LSE:AZN XPAR:SAN LSE:GSK TSE:4519 TSE:4568
Traded in Other Exchanges
GILD:USA GILD:Peru GILD:Mexico 1GILD:Italy 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD:Chile GILD34:Brazil GILD:Austria GILD:Argentina
Address
333 Lakeside Drive, Foster, CA, USA, 94404
Website
https://www.gilead.com
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences Headlines

No Headlines